E
Etienne De Braekeleer
Researcher at Wellcome Trust Sanger Institute
Publications - 45
Citations - 2766
Etienne De Braekeleer is an academic researcher from Wellcome Trust Sanger Institute. The author has contributed to research in topics: Myeloid leukemia & Fusion gene. The author has an hindex of 16, co-authored 43 publications receiving 1701 citations. Previous affiliations of Etienne De Braekeleer include University of Western Brittany & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Promoter-bound METTL3 maintains myeloid leukaemia by m 6 A-dependent translation control
Isaia Barbieri,Konstantinos Tzelepis,Luca Pandolfini,Junwei Shi,Gonzalo Millán-Zambrano,Samuel Robson,Demetrios Aspris,Valentina Migliori,Andrew J. Bannister,Namshik Han,Etienne De Braekeleer,Hannes Ponstingl,Alan G. Hendrick,Christopher R. Vakoc,George S. Vassiliou,Tony Kouzarides +15 more
TL;DR: Together, these data define METTL3 as a regulator of a chromatin-based pathway that is necessary for maintenance of the leukaemic state and identify this enzyme as a potential therapeutic target for acute myeloid leukaemia.
Journal ArticleDOI
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
Konstantinos Tzelepis,Hiroko Koike-Yusa,Etienne De Braekeleer,Yang Li,Emmanouil Metzakopian,Oliver M. Dovey,Annalisa Mupo,Vera V. Grinkevich,Meng Li,Milena Mazan,Malgorzata Gozdecka,Shuhei Ohnishi,Jonathan L. Cooper,Miten Patel,Thomas McKerrell,Bin Chen,Ana Domingues,Paolo Gallipoli,Sarah A. Teichmann,Hannes Ponstingl,Ultan McDermott,Julio Saez-Rodriguez,Julio Saez-Rodriguez,Brian J. P. Huntly,Francesco Iorio,Cristina Pina,George S. Vassiliou,George S. Vassiliou,Kosuke Yusa +28 more
TL;DR: KAT2A inhibition demonstrated anti-AML activity by inducing myeloid differentiation and apoptosis, and suppressed the growth of primary human AMLs of diverse genotypes while sparing normal hemopoietic stem-progenitor cells.
Journal ArticleDOI
Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.
Eliza Yankova,Eliza Yankova,Wesley Blackaby,Mark Albertella,Justyna Rak,Justyna Rak,Etienne De Braekeleer,Etienne De Braekeleer,Georgia Tsagkogeorga,Ewa S. Pilka,Demetrios Aspris,Dan Leggate,Alan G. Hendrick,Natalie A. Webster,Byron Andrews,Richard Fosbeary,Patrick Guest,Nerea Irigoyen,Maria Eleftheriou,Malgorzata Gozdecka,João Lopes Dias,Andrew J. Bannister,Binje Vick,Irmela Jeremias,George S. Vassiliou,George S. Vassiliou,Oliver Rausch,Konstantinos Tzelepis,Tony Kouzarides +28 more
TL;DR: In this article, a first-in-class catalytic inhibitor of METTL3 was identified and characterized, and a crystal structure of STM2457 in complex with METTL 3 and METTL14 was presented.
Journal ArticleDOI
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.
Joanne I. Hsu,Joanne I. Hsu,Tajhal Dayaram,Ayala Tovy,Etienne De Braekeleer,Etienne De Braekeleer,Mira Jeong,Feng Wang,Jianhua Zhang,Timothy P. Heffernan,Sonal Gera,Jeffrey J. Kovacs,Joseph R. Marszalek,Christopher A. Bristow,Yuanqing Yan,Guillermo Garcia-Manero,Hagop M. Kantarjian,George S. Vassiliou,George S. Vassiliou,P. Andrew Futreal,Lawrence A. Donehower,Koichi Takahashi,Margaret A. Goodell,Margaret A. Goodell +23 more
TL;DR: It is found that mutations in PPM1D (protein phosphatase Mn2+/Mg2+-dependent 1D), a DNA damage response regulator that is frequently mutated in CH, were present in one-fifth of patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome and strongly correlated with cisplatin exposure.
Journal ArticleDOI
ETV6 fusion genes in hematological malignancies: a review.
Etienne De Braekeleer,Nathalie Douet-Guilbert,Frédéric Morel,Marie-Josée Le Bris,Audrey Basinko,Marc De Braekeleer +5 more
TL;DR: Five potential mechanisms of ETV6-mediated leukemogenesis have been identified: constitutive activation of the kinase activity of the partner protein, modification of the original functions of a transcription factor, loss of function of the fusion gene, and activation of a proto-oncogene in the vicinity of a chromosomal translocation.